WT1 polyclonal antibody

Product Specifications

Background

Wilms' tumor (WT) is an embryonal malignancy of the kidney that affects 1 in 10,000 infants and, like retinoblastoma, is observed in both sporadic and inherited forms. The Wilms' tumor locus has been mapped at chromosome 11p13 as a tumor suppressor gene which encodes a DNA binding protein with four zinc fingers and a glutamine-proline rich amino-terminus. The Wilms' tumor protein (WT1) binds the DNA sequence GCGGGGGCG, a recognition element common to the early growth response (Egr) family of Zn2+ finger transcriptional activators. However, in contrast to Egr transcription factors, WT1 behaves as a transcriptional repressor in transient transfection assays with synthetic promotor constructs.

CAS Number

9007-83-4

Structure Composition

0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Product Name Alternative

WIT 2; WT 1; AWT1; FWT1; GUD; NPHS4; WAGR; Wilms tumor 1; Wilms Tumor; Wilms tumor protein; Wilms' tumor gene; Wilms' tumor protein; WIT2; WT; WT1; WT-1; WT1_HUMAN; WT33

Swiss Prot

P19544

Reactivity

Human, Mouse, Rat

Immunogen

KLH conjugated synthetic peptide derived from human WT1: 301-400/449

Conjugation

Unconjugated

Applications

WB IF IHC ELISA

Dilution

WB: 1:500~1:2000 IHC: 1:100~1:500 IF: 1:100~1:500 ELISA: 1:5000~1:10000

Purity

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .